Tecan Group AG (TCHBF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Tecan Group AG (TCHBF) trades at $198.00 with AI Score 44/100 (Grade C). Tecan Group AG provides laboratory instruments and solutions for pharmaceutical and biotechnology companies, university research departments, and forensic and diagnostic laboratories. Market cap: $2.51B, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for TCHBF: TCHBF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates TCHBF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
TCHBF: the 1 perspectives are evenly split.
How is this calculated? →Tecan Group AG (TCHBF) Healthcare & Pipeline Overview
Tecan Group AG, a Swiss-based company, provides advanced laboratory instruments and automation solutions for the life sciences and diagnostics markets. With a focus on liquid handling, detection, and automation, Tecan serves pharmaceutical, biotechnology, and research institutions globally, maintaining a strong position in a competitive healthcare landscape.
What Is the Investment Thesis for TCHBF?
Tecan Group AG presents a notable research candidate within the laboratory automation and life sciences sector. With a P/E ratio of 24.49 and a profit margin of 7.0%, the company demonstrates stable profitability. A dividend yield of 2.47% offers an income stream for investors. Growth catalysts include expanding automation solutions and increasing demand for NGS reagents. Potential risks include competition from established players and fluctuations in research funding. The company's beta of 1.25 indicates higher volatility compared to the market. Tecan's gross margin of 35.2% reflects its ability to maintain profitability in a competitive environment. Key value drivers include innovation in automation technology and strategic partnerships within the healthcare sector.
Based on FMP financials and quantitative analysis
TCHBF Key Highlights
- Market capitalization of $2.51B, indicating a significant presence in the laboratory instruments market.
- P/E ratio of 24.49, suggesting a reasonable valuation relative to earnings.
- Profit margin of 7.0%, demonstrating the company's ability to generate profits from its operations.
- Gross margin of 35.2%, reflecting efficient cost management in production and sales.
- Dividend yield of 2.47%, providing a steady income stream for investors.
Who Are TCHBF's Competitors?
TCHBF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ANSLF Ansell Limited | $19.58 | +0.00% | $2.77B | 57 |
| ANSLY Ansell Limited | $81.94 | -2.56% | $2.89B | 56 |
| GGNDF GN Store Nord A/S | $14.35 | +7.17% | $2.09B | 41 |
| GNNDY GN Store Nord A/S | $41.25 | -0.10% | $2.00B | 44 |
| HAWPY Haw Par Corporation Limited | $54.44 | +1.76% | $3.01B | 50 |
| NYXH Nyxoah S.A. | $1.75 | +1.74% | $69.31M | 69 |
| KMTS Kestra Medical Technologies, Ltd. | $27.70 | +2.67% | $1.62B | 67 |
| ZTEK Zentek Ltd. | $0.46 | +2.88% | $49.90M | 63 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are TCHBF's Key Strengths?
- Strong market position in laboratory automation.
- Diverse product portfolio serving multiple customer segments.
- Global presence with operations in key markets.
- Established relationships with leading pharmaceutical and biotechnology companies.
What Are TCHBF's Weaknesses?
- Dependence on research funding and healthcare expenditures.
- Exposure to currency fluctuations due to international operations.
- Limited brand recognition compared to larger competitors.
- Potential for product obsolescence due to rapid technological advancements.
What Could Drive TCHBF Stock Higher?
- Expansion of automation solutions into new therapeutic areas.
- Increasing demand for NGS reagents and consumables.
- Strategic partnerships with diagnostic companies (2026-2027).
- Geographic expansion in the Asian market.
- Continuous innovation in automation technology.
What Are the Key Risks for TCHBF?
- Negative return on equity (-9.1%) — the business is not currently generating profit on shareholder capital.
- Intense competition from established players in the laboratory instruments market.
- Economic downturns affecting research funding and healthcare spending.
- Regulatory changes impacting the laboratory instruments market.
- Disruptive technologies challenging existing automation solutions.
- Exposure to currency fluctuations due to international operations.
What Are the Growth Opportunities for TCHBF?
- Expansion in NGS Reagents: Tecan can capitalize on the growing market for Next-Generation Sequencing (NGS) reagents. The global NGS market is projected to reach $25 billion by 2028, driven by advancements in genomics and personalized medicine. Tecan's expertise in liquid handling and automation positions it to develop and market high-quality NGS reagents, capturing a significant share of this expanding market. Timeline: Ongoing.
- Strategic Partnerships in Diagnostics: Forming strategic partnerships with diagnostic companies can drive growth for Tecan. The diagnostics market is experiencing rapid growth due to increasing demand for early disease detection and personalized healthcare. By collaborating with diagnostic firms, Tecan can integrate its automation solutions into diagnostic workflows, expanding its market reach and revenue streams. Timeline: Ongoing.
- Geographic Expansion in Asia: Expanding its presence in the Asian market presents a significant growth opportunity for Tecan. The Asian healthcare market is growing rapidly, driven by increasing healthcare expenditures and a growing middle class. By establishing a stronger presence in Asia, Tecan can tap into this expanding market and increase its global market share. Timeline: 2026-2028.
- Innovation in Automation Technology: Continuous innovation in automation technology is crucial for Tecan's growth. The demand for high-throughput screening and automated workflows is increasing in the pharmaceutical and biotechnology industries. By developing advanced automation solutions, Tecan can attract new customers and retain existing ones, driving revenue growth and market leadership. Timeline: Ongoing.
- Development of Consumables: Expanding the portfolio of consumables can provide a recurring revenue stream for Tecan. Consumables, such as pipette tips and microplates, are essential for laboratory workflows. By developing and marketing high-quality consumables, Tecan can generate a steady stream of revenue and increase customer loyalty. The global market for laboratory consumables is expected to grow steadily, providing a stable growth opportunity for Tecan. Timeline: Ongoing.
What Opportunities Does TCHBF Have?
- Expansion into emerging markets with growing healthcare sectors.
- Development of new automation solutions for personalized medicine.
- Strategic partnerships with diagnostic companies.
- Increased demand for NGS reagents and consumables.
What Threats Does TCHBF Face?
- Intense competition from established players.
- Economic downturns affecting research funding and healthcare spending.
- Regulatory changes impacting the laboratory instruments market.
- Disruptive technologies challenging existing automation solutions.
What Are TCHBF's Competitive Advantages?
- Proprietary Technology: Tecan's advanced automation technology and liquid handling systems provide a competitive edge.
- Established Customer Base: Long-standing relationships with leading pharmaceutical and biotechnology companies create customer loyalty.
- Global Presence: Operations in key markets worldwide enable Tecan to serve a global customer base.
- Strong Brand Reputation: Tecan is recognized as a trusted provider of high-quality laboratory instruments and solutions.
What Does TCHBF Do?
Tecan Group AG, founded in 1980 and headquartered in Männedorf, Switzerland, is a leading global provider of laboratory instruments and solutions. The company serves a diverse range of customers, including pharmaceutical and biotechnology companies, university research departments, and forensic and diagnostic laboratories. Tecan operates through two primary segments: Life Sciences Business and Partnering Business. The Life Sciences Business focuses on providing end-user solutions, including liquid handling and automation, microplate readers and washers, consumables, NGS reagents, immunoassays and microbodies, and software. Key offerings include Tecan Laberwax, an automation solution, and Resolvex, a smart sample preparation solution. The Partnering Business develops and manufactures essential components for laboratory instrument manufacturers, such as precision pumps, valves, robotic arms, and developer software. These components are used in life science research, diagnostics, and various other industries. Tecan's product portfolio includes Synergence, a platform-based automation solution, and Freedom EVO and Fluent instruments. The company has a global presence, operating in Switzerland, other European countries, North America, and Asia.
What Products and Services Does TCHBF Offer?
- Provides liquid handling and automation solutions for laboratories.
- Offers microplate readers and washers for various applications.
- Develops and manufactures consumables for laboratory workflows.
- Supplies NGS reagents for next-generation sequencing.
- Offers immunoassays and microbodies for research and diagnostics.
- Provides software solutions for laboratory automation.
- Manufactures precision pumps, valves, and robotic arms for instrument manufacturers.
How Does TCHBF Make Money?
- Sells laboratory instruments and automation solutions to pharmaceutical, biotechnology, and research institutions.
- Generates revenue from the sale of consumables and reagents.
- Provides maintenance and support services for its instruments.
- Partners with other companies to integrate its technology into their products.
What Industry Does TCHBF Operate In?
Tecan Group AG operates in the medical instruments and supplies industry, which is characterized by continuous innovation and increasing demand for automation. The market is driven by the growing need for high-throughput screening, personalized medicine, and advanced diagnostics. Key trends include the integration of artificial intelligence and machine learning in laboratory automation. Tecan competes with companies like ANSLF (Agilent Technologies), ANSLY (Agilent Technologies), GGNDF (Danaher Corporation), GNNDY (Danaher Corporation), and HAWPY (Thermo Fisher Scientific), all vying for market share in the life sciences and diagnostics sectors. The industry is expected to grow steadily, driven by increasing healthcare expenditures and advancements in biotechnology.
Who Are TCHBF's Key Customers?
- Pharmaceutical companies involved in drug discovery and development.
- Biotechnology companies focused on genomics, proteomics, and cell biology.
- University research departments conducting basic and applied research.
- Forensic laboratories performing DNA analysis and other forensic testing.
- Diagnostic laboratories providing clinical testing services.
FY2026 estForward Outlook
Wall Street analysts project Tecan Group AG revenue of about $870.5M for fiscal 2026, with EPS near $5.92. The estimate reflects 8 contributing analysts.
ROE -9%Key Financial Metrics
Return on equity for Tecan Group AG stands at -9.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -6.5%, showing how much profit it generates from its asset base. Its free cash flow yield is 4.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.46 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -4.8%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 4/9Financial Health
Tecan Group AG's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 4.65 places it in the safe zone, indicating low near-term bankruptcy risk.
TCHBF Valuation & Market Position
With a $2.51B market cap, Tecan Group AG sits in the mid-cap segment of the market. Relative to its peer group, TCHBF's quantitative score of 44/100 is roughly in line with the peer average of 50/100.
TCHBF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Strong market position in laboratory automation.
- Diverse product portfolio serving multiple customer segments.
- Global presence with operations in key markets.
- Established relationships with leading pharmaceutical and biotechnology companies.
Bear Case
- Dependence on research funding and healthcare expenditures.
- Exposure to currency fluctuations due to international operations.
- Limited brand recognition compared to larger competitors.
- Potential for product obsolescence due to rapid technological advancements.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
TCHBF Latest News
No recent news available for TCHBF.
TCHBF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for TCHBF.
Price Targets
Wall Street price target analysis for TCHBF.
TCHBF MoonshotScore
What does this score mean?
The MoonshotScore rates TCHBF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Monica Manotas
CEO
Monica Manotas serves as the CEO of Tecan Group AG, leading a global team of 3074 employees. Her background includes extensive experience in the healthcare and life sciences industries. Prior to joining Tecan, she held leadership positions at various multinational corporations, focusing on strategic planning, business development, and operational excellence. She holds an MBA from a leading business school and a degree in engineering.
Track Record: Under Monica Manotas's leadership, Tecan Group AG has focused on expanding its automation solutions and strengthening its presence in key markets. She has overseen the launch of new products and services, driving revenue growth and market share. Her strategic decisions have focused on innovation, customer satisfaction, and operational efficiency. She has also emphasized sustainability and corporate social responsibility.
TCHBF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Tecan Group AG (TCHBF) may have limited regulatory oversight and reporting requirements compared to companies listed on major exchanges like the NYSE or NASDAQ. Companies in this tier may not meet the minimum financial standards required for higher tiers or exchange listings. Investors should be aware that companies in this tier may present higher risks due to limited information and regulatory scrutiny. Trading on the OTC Other tier does not guarantee the legitimacy or financial health of the company.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited regulatory oversight and reporting requirements.
- Potential for lower liquidity and wider bid-ask spreads.
- Increased price volatility due to lower trading volume.
- Higher risk of fraud or mismanagement compared to exchange-listed companies.
- Limited access to company information and financial disclosures.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Check for any legal or regulatory issues.
- Monitor trading volume and price activity.
- Consult with a financial advisor before investing.
- Established history of operations since 1980.
- Presence in multiple geographic regions.
- Partnerships with reputable companies in the healthcare sector.
- Positive customer reviews and testimonials.
- Active participation in industry events and conferences.
What Investors Ask About Tecan Group AG (TCHBF) — Healthcare
What does Tecan Group AG do?
Tecan Group AG specializes in providing laboratory instruments and automation solutions for the healthcare and life sciences industries. The company develops and manufactures a range of products, including liquid handling systems, microplate readers, and consumables. These products are used in pharmaceutical and biotechnology companies, university research departments, and diagnostic laboratories to automate and streamline laboratory workflows. Tecan's solutions enable researchers and clinicians to improve efficiency, accuracy, and reproducibility in their experiments and analyses. The company operates through two segments: Life Sciences Business and Partnering Business.
What do analysts say about TCHBF stock?
Analyst coverage of Tecan Group AG (TCHBF) is limited due to its OTC listing. However, key valuation metrics such as the P/E ratio of 24.49 and the dividend yield of 2.47% provide insights into the company's financial performance. Growth considerations include the increasing demand for laboratory automation and NGS reagents. Investors should conduct their own due diligence and consider the risks associated with OTC-listed stocks. Analyst consensus is not readily available due to the limited coverage.
What are the main risks for TCHBF?
Tecan Group AG faces several risks, including intense competition from established players in the laboratory instruments market, economic downturns affecting research funding and healthcare spending, regulatory changes impacting the market, and disruptive technologies challenging existing automation solutions. Additionally, the company is exposed to currency fluctuations due to its international operations. As an OTC-listed stock, TCHBF also faces risks associated with limited regulatory oversight and lower liquidity.
What are the key growth opportunities for TCHBF in healthcare?
Tecan Group AG's growth opportunities in healthcare include expanding its automation solutions into new therapeutic areas, forming strategic partnerships with diagnostic companies, and increasing its presence in emerging markets with growing healthcare sectors. The company can also capitalize on the increasing demand for NGS reagents and consumables, as well as the development of new automation solutions for personalized medicine. These opportunities align with the broader trends in the healthcare industry, such as the increasing adoption of automation and the growing focus on personalized healthcare.
What revenue streams does Tecan Group AG have in healthcare?
Tecan Group AG generates revenue from several key streams within the healthcare sector. These include the sale of laboratory instruments and automation solutions to pharmaceutical and biotechnology companies, university research departments, and diagnostic laboratories. Revenue is also derived from the sale of consumables and reagents, as well as maintenance and support services for its instruments. Additionally, Tecan generates revenue through partnerships with other companies to integrate its technology into their products. These revenue streams are diversified across different customer segments and geographic markets.
What are the key factors to evaluate for TCHBF?
Tecan Group AG (TCHBF) holds an AI score of 44/100 (low). Not financial advice.
How frequently does TCHBF data refresh on this page?
TCHBF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven TCHBF's recent stock price performance?
Tecan Group AG (TCHBF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong market position in laboratory automation. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited analyst coverage due to OTC listing.
- Financial data based on available sources and may not be fully comprehensive.